References (Products)

Product Catalog #
Reference
ColonyGEL™ (Human Base) 1101 Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia,” Lee-Sherick, A.B. et al., Oncogene, 32(46): 5359-68, November 14, 2013.  Department of Pediatrics, Division of Hematology, Oncology, and Bone Marrow Transplantation, Aurora, CO, USA.
ColonyGEL™ (Human Enriched Complete) 1104 Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity,” Pardee, T.S. et al, Blood, 119(15): 3561-3570, April 12, 2012. Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston-Salem, NC.
ColonyGEL™ (Mouse Complete) 1202 Erythroid cells generated in the absence of specific β1-integrin heterodimers accumulate reactive oxygen species at homeostasis and are unable to mount effective antioxidant defenses,” Ulyanova, T. et al, Haematologica, 98(11): 1769-1777, 2013. Dept. of Medicine, Div. of Hematology, University of Washington, Seattle, USA.
ColonyGEL™ (Human Base) 1101 Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia,” Linger R.M et al., Blood, 122(9): 1599-609, August 29, 2013.  Department of Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
ColonyGEL™ (Mouse Base) 1201 Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis,” Tao, L. et al., Molecular Cancer, 12(55): 1-11, June 10, 2013. Department of Orthopaedic Surgery, UC Irvine Multidisciplinary Sarcoma Center, Chao Family Comprehensive Cancer Center, University of California, Irvine, USA.
ColonyGEL™ (Mouse Base) 1201 Dietary feeding of flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in mice,” Li, X. et al., Toxicology Reports, 1: 2-11, 2014. Department of Urology, University of California Irvine, Orange, CA.
ColonyGEL™ (Human Base) 1101 Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia,” Brandao, L.N. et al.,  Blood Cancer J., 3: 1-9, January 25, 2013 (e101). Department of Pediatrics, Section of Hematology, Oncology and Bone Marrow Transplantation, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
ColonyGEL™ (Mouse Complete without EPO) 1203 LINE-1-derived poly(A) microsatellites undergo rapid shortening and create somatic and germline mosaicism in mice,” Grandi, F.C. et al.,  Mol Biol Evol., 30(3): 503-12, March 2013. School of Molecular Biosciences and Center for Reproductive Biology, Washington State University, Pullman, WA.
ColonyGEL™ (Human Base) 1101 Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia,” Christoph, S. et al., J Vis Exp., 79: e50720, September 18, 2013.  Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO.
ColonyGEL™ (Human Base) 1101 UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo,”  Christoph, S. et al.,  Mol Cancer Ther., 12(11): 2367-77, November 2013. University of Colorado Anschutz Medical Campus, Aurora, CO.
Human Peripheral Blood MNC (PBMC) 0500-301 A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys,” Smith E.J.,1 Olson K.,1 Haber L.J.,1 Varghese B.,1 Duramad P.,1 Tustian A.D.,1 Oyejide A.,1 Kirshner J.R.,1 Canova L.,1 Menon J.,1 Principio J.,1 MacDonald D.,1 Kantrowitz J.,1 Papadopoulos N.,1 Stahl N.,1 Yancopoulos G.D.,1 Thurston G.,1 Davis S.,1. Sci Rep.: 1-12, 2015 Dec 11; 5. doi: 10.1038/srep17943.  1Regeneron Pharmaceuticals, Tarrytown, NY, USA.
Human Mesenchymal Stem Cells (MSC) 02100 Mesenchymal stem cell mechanics from the attached to the suspended state,” Maloney, J.M. et al., Biophys J. 99(8): 2479-87, October 20, 2010. Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, USA.
Human Mesenchymal Stem Cells (MSC) 02100 Mechanical fluidity of fully suspended biological cells,” Maloney, J.M. et al., Biophys J., 105(8): 1767-77, October 15, 2013. Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Human Mesenchymal Stem Cells (MSC) 02100 Macromolecular crowding directs extracellular matrix organization and mesenchymal stem cell behavior,” Zeiger, A.S. et al., PLoS One, 7(5): e37904, 2012. Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Human Mesenchymal Stem Cells (MSC) 02100 Why the dish makes a difference: quantitative comparison of polystyrene culture surfaces,” Zeiger, A.S. et al., Acta Biomater., 9(7): 7354-61, 2013. Department of Materials Science & Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Human Mesenchymal Stem Cells (MSC) 02100 Onset of heterogeneity in culture-expanded bone marrow stromal cells,” Whitfield, M.J. et al., Stem Cell Res., 11(3):1365-77, November 2013. Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Human CD14+ Monocytes 0514-201 IFI16 protein mediates the anti-inflammatory actions of the type-I interferons through suppression of activation of caspase-1 by inflammasomes,” Veeranki, S. et al.,Plos One, 6(10): e27040, October 28, 2011. Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA.
Human CD19+ B Cells 0519-101 IFI16 protein mediates the anti-inflammatory actions of the type-I interferons through suppression of activation of caspase-1 by inflammasomes,” Veeranki, S. et al.,Plos One, 6(10): e27040, October 28, 2011. Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio, USA.
Human CD14+ Monocytes 0514-101 Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes and CD34 (+) cells,” Rossetto, C.C. et al.,  PLoS Pathog., 9(5): e1003366, May 23, 2013. The University of Nevada, Reno School of Medicine, Department of Microbiology & Immunology, Reno, Nevada, USA.
Human CD14+ Monocytes 0514-201 Characterization of Macrophage Behavior in the Human Immunoresponse and Bone Remodeling,” Davies, J. et al., Vanderbilt University Young Scientist Publication, May 2013. Vanderbilt University.
Human CD14+ Monocytes 0514-100 Vascular Endothelial Tight Junctions and Barrier Function Are Disrupted by 15(S)-Hydroxyeicosatetraenoic Acid Partly via Protein Kinase C{epsilon}-mediated Zona Occludens-1 Phosphorylation at Threonine 770/772,” Chattopadhyay, R. et al., J Biol Chem., 289(6):3148-63, February 7, 2014. From the Department of Physiology, University of Tennessee Health Science Center, Memphis, TN.